Investor mix
3 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 33% |
| Bank & private debt | 1 | 33% |
| Other / undisclosed | 1 | 33% |
Develops therapeutic monoclonal antibodies for cancer and inflammatory diseases
3 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Private equity | 1 | 33% |
| Bank & private debt | 1 | 33% |
| Other / undisclosed | 1 | 33% |